Home / Medical/Health Care / Detailed Results Demonstrate Baricitinib Superiority to Adalimumab in Improving Signs and Symptoms of Rheumatoid Arthritis

Detailed Results Demonstrate Baricitinib Superiority to Adalimumab in Improving Signs and Symptoms of Rheumatoid Arthritis

Once-daily oral baricitinib significantly improved all seven components of ACR response versus injectable adalimumab

Patient-reported pain, joint stiffness, fatigue and physical function scores significantly improved with baricitinib compared

Comments are closed.

Scroll To Top